La chaîne d'options affiche les données clés des options sur actions de Rocket Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Rocket Pharmaceuticals..

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock, Chaîne d'Options

ROCKET PHARMACEUTICALS INC

Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals Inc

ROCK TECH LINTHIUM INC by Rock Tech Lithium Inc.

Rock Tech Lithium Inc

News

NEGG

Newegg Commerce Announces Exclusive Availability Of AMD EPYC 4005 Series Processors In North America Retail Launch

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Kelly Shi initiated coverage on Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy rating and announced a price target of $105. Insmed shares closed at $67.75 on Monday. <a href="https://www.benzinga.com/quote/INSM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Edward DeArias initiated coverage on Black Hills Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKH#NYSE">BKH</a>) with an Outperform rating and announced a price target of $68. Black Hills shares closed at $58.07 on Monday. <a href="https://www.benzinga.com/quote/BKH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Edward DeArias initiated coverage on Evergy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVRG#NASDAQ">EVRG</a>) with an Outperform rating and announced a price target of $75. Evergy shares closed at $65.35 on Monday. <a href="https://www.benzinga.com/quote/EVRG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Edward DeArias initiated coverage on Portland General Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Market Perform rating and announced a price target of $46. Portland Gen Electric shares closed at $42.62 on Monday. <a href="https://www.benzinga.com/quote/POR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Edward DeArias initiated coverage on Pinnacle West Capital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) with a Market Perform rating and announced a price target of $95. Pinnacle West Capital shares closed at $90.07 on Monday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying INSM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145-1024x601.png" alt="" class="wp-image-913464" style="width:593px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145.png 1076w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Initiation

Markets

Analyst Ratings

Trading Ideas

EVRG

INSM

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Lifeway Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.19 by 21.05 percent. This is a 43.75 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $46.09 million which missed the analyst consensus estimate of $48.50 million by 4.97 percent. This is a 3.26 percent increase over sales of $44.63 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

LWAY

Lifeway Foods Q1 EPS $0.23 Beats $0.19 Estimate, Sales $46.09M Miss $48.50M Estimate

BMO Capital analyst Ameet Thakkar downgrades Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) from Market Perform to Underperform and lowers the price target from $46 to $39.

Downgrades

Price Target

ENPH

BMO Capital Downgrades Enphase Energy to Underperform, Lowers Price Target to $39

Buybacks

Western Digital Authorizes New $2B Share Repurchase Program

Marui Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MAURY#OTC">MAURY</a>) reported quarterly earnings of $0.54 per share. This is a 5.88 percent increase over earnings of $0.51 per share from the same period last year. The company reported $436.79 million in sales this quarter. This is a 0.13 percent increase over sales of $436.20 million the same period last year.

MAURY

Marui Group Q4 EPS $0.54 Up From $0.51 YoY, Sales $436.79M Up From $436.20M YoY

JAKK

JAKKS Pacific's Disguise Announces Multi-Year Contract Extension With PhatMojo To Expand Rainbow Friends Brand Across North America And Europe

In a recent address at the China-CELAC Forum in Beijing, Chinese President Xi Jinping spoke about tariffs and trade war for the first time since the 90-day tariff relaxation between the U.S. and China. He also pledged economic support to LatAm and Caribbean countries and called for the region to come together to counter the growing influence of the U.S.
What Happened: President Xi Jinping emphasized the importance of international cooperation during his keynote address at the fourth ministerial meeting of the China-CELAC (Community of Latin American and Caribbean States) Forum on Tuesday, as reported by&nbsp;<a href="https://www.chinadailyasia.com/hk/article/611615">China Daily</a>. &#8220;There are no winners in tariff wars and trade wars,&#8221; stated Xi and added, &#8220;bullying and hegemony will only result in self-isolation,&#8221; indirectly referring to the U.S.
Xi expressed China&#8217;s willingness to strengthen solidarity with Latin American and Caribbean nations, pledging continued mutual support on key interests and major concerns. Xi noted that in 2024, trade between China and Latin American and Caribbean countries surpassed $500 billion for the first time—over 40 times the volume recorded at the beginning of the century.
According to Reuters, President Xi Jinping pledged to expand China's influence in Latin America and the Caribbean by offering a new $9 billion credit line and increasing infrastructure investments in the region.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/earnings/25/05/45353123/quantum-stocks-are-hot-in-2025-biggest-movers-to-watch" target="_blank" rel="noreferrer noopener">Quantum Stocks Are Hot In 2025: Biggest Movers To Watch</a>
Why It Matters: The Chinese President&#8217;s remarks come against the backdrop of a turbulent trade relationship with the United States. Economist Nouriel Roubini had earlier stated that President Donald Trump <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45367790/dr-doom-nouriel-roubini-says-trump-chickened-out-in-trade-war-with-china-calls-xi-jinping-the-clear-winner-after-tariff-rollback">had backed down</a> in his trade confrontation with China, with almost no concessions from the Chinese side.
Nonetheless, after the tariff truce, China resumed accepting Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) <a href="https://www.benzinga.com/25/05/45368534/china-greenlights-boeing-jet-arrivals-again-as-90-day-tariff-pause-with-us-brings-relief">aircraft deliveries</a> after a month-long pause, following a significant trade breakthrough with the United States. 
Notably, this is not the first time Xi Jinping has spoken against bullying on the trade front. In April 2025, the Chinese President had embarked on a diplomatic tour of Southeast Asia, advocating for<a href="https://www.benzinga.com/markets/25/04/44806095/as-xi-jinping-urges-vietnam-to-stand-against-unilateral-bullying-trump-labels-the-meeting-a-plan-to-screw-the-united-states-of-america"> free trade</a> and unity against "unilateral bullying.&#8221;
While China is stepping up efforts to increase influence on Latin American countries, Brazilian President Luiz Inácio Lula da Silva told his countrymen, &#8220;It&#8217;s important to understand, (the fate of Latin America) doesn&#8217;t depend on anyone else. It does not depend on President Xi Jinping, it does not depend on the United States, it does not depend on the European Union, it depends solely and simply on whether we want to be great or continue to be small,&#8221; reported Reuters.<a href="https://en.wikipedia.org/wiki/Luiz_In%C3%A1cio_Lula_da_Silva"></a>
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/05/45369487/josh-hawley-slams-gop-identity-crisis-over-medicaid-calls-proposed-cuts-morally-wrong-and-politically-suicidal" target="_blank" rel="noreferrer noopener">Josh Hawley Slams GOP &#8216;Identity Crisis&#8217; Over Medicaid, Calls Proposed Cuts &#8216;Morally Wrong And Politically Suicidal&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Xi Jinping Warns 'Bullying And Hegemony Will Only Result In Self-Isolation' In First Remarks Since US-China Tariff Suspension

The CBIZ Tariff Solution includes:
<ul>
<li>Tariff Impact Modeling &amp; Pricing Strategy</li>
<li>Supply Chain &amp; Duty Mitigation Planning</li>
<li>Transfer Pricing &amp; International Tax Advisory</li>
<li>State &amp; Local Incentives for Reshoring</li>
<li>Trade Remedies &amp; Compliance Guidance</li>
<li>Financial Reporting, Disclosure, and Risk Control Support</li>
</ul>

General

CBIZ Launches CBIZ Tariff Solution

he partnership will help LiqTech:
<ul>
<li>Accelerate revenue growth through U.S. market entry.</li>
<li>Expand recurring revenue opportunities via long-term system installations.</li>
<li>Strengthen its position as a leader in sustainable water filtration solutions.</li>
</ul>

LIQT

LiqTech International Signs Agreements With NAF Aquatics For U.S. Commercial Swimming Pool Market

WIIM

Merck shares are trading lower. The company highlighted MK-1084 data from KANDLELIT-001 in KRAS G12C-mutated colorectal and lung cancers.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

UPXI

Upexi To Use BitGo's OTC Trading Services To Manage Its Digital Asset Portfolio

– Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 –
– On track to initiate similarly-designed Phase 2 study in patients with COPD imminently –

Biotech

CNTB

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart For Acute Exacerbations In Asthma

Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Terex, revealing an average target of $45.5, a high estimate of $66.00, and a low estimate of $30.00. Observing a downward trend, the current average is 8.69% lower than the prior average price target of $49.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1747141285_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Terex is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mircea Dobre</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Courtney Yakavonis</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$47.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$32.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$59.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Terex. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Terex compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Terex's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Terex's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TEX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Terex analyst ratings.</a>
<h2>All You Need to Know About Terex</h2>
Terex Corp is a manufacturer of materials processing machinery, waste and recycling solutions, mobile elevating work platforms (MEWPs), and equipment for the electric utility industry. The company designs builds, and supports products used in maintenance, manufacturing, energy, waste and recycling, minerals and materials management, construction, and the entertainment industry. The products are manufactured in North America, Europe, and Asia Pacific and sold all over the world. The company reports business in the following segments: (i) Materials Processing, (ii) Aerial Work Platforms, and (iii) Environmental Solutions Group.
<h3>Terex: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Terex's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -4.88% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 1.71%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Terex's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.14%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Terex's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.36%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Terex's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.4, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Have This To Say About Terex

Across the recent three months, 5 analysts have shared their insights on Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $50.0, a high estimate of $84.00, and a low estimate of $36.00. This current average has decreased by 3.1% from the previous average price target of $51.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1747141268_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Dianthus Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dianthus Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dianthus Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Dianthus Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Dianthus Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DNTH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dianthus Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Dianthus Therapeutics: A Closer Look</h2>
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
<h3>Dianthus Therapeutics's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Dianthus Therapeutics displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 190.15%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dianthus Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2144.8%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Dianthus Therapeutics's ROE excels beyond industry benchmarks, reaching -8.24%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.81%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Dianthus Therapeutics's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DNTH

Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views

Macquarie analyst Paul Golding maintains Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) with a Neutral and maintains $95 price target.

PLNT

Macquarie Maintains Neutral on Planet Fitness, Maintains $95 Price Target

Analysts' ratings for Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) over the last quarter vary from bullish to bearish, as provided by 19 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">13</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $34.74, a high estimate of $45.00, and a low estimate of $21.00. A 14.09% drop is evident in the current average compared to the previous average price target of $40.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1747141254_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Rapid7 by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$21.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Erin Wilson</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Todd Weller</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Erin Wilson</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Adam Tindle</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$35.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Rapid7. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Rapid7 compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Rapid7's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Rapid7's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RPD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Rapid7 analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Rapid7 Better</h2>
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
<h3>Rapid7: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Rapid7 showcased positive performance, achieving a revenue growth rate of 5.36% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Rapid7's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -0.68%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Rapid7's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -25.97%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Rapid7's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.09%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 57.49, Rapid7 faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

19 Analysts Assess Rapid7: What You Need To Know

12 analysts have expressed a variety of opinions on Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $341.25, a high estimate of $450.00, and a low estimate of $290.00. A 6.4% drop is evident in the current average compared to the previous average price target of $364.58. 
<img src="https://www.benzinga.com/files/images/story/2025/1747141246_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Monday.Com among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$330.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$310.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$305.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Lucky Schreiner</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$290.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$360.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$315.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Lucky Schreiner</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$340.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Monday.Com. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Monday.Com compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Monday.Com's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Monday.Com's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MNDY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Monday.Com analyst ratings.</a>
<h2>Unveiling the Story Behind Monday.Com</h2>
Monday.com is a provider of work management software delivered via a cloud-based software-as-a-service, or SaaS model. The firm's solutions offer flexible and highly customizable tools to digitize business processes across countless use cases. Monday's offering supports workflow management across departments, real-time visibility and accountability, and automation capabilities. Monday also offers prepackaged CRM and DevOps management solutions, in addition to standalone survey and digital whiteboard tools. As of 2023, Monday served over 225,000 customers in more than 200 countries.
<h3>Financial Insights: Monday.Com</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Monday.Com's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 32.29% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.58%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.3%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.41%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.1, Monday.Com adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MNDY

Forecasting The Future: 12 Analyst Projections For Monday.Com

Kinsale Cap Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) short percent of float has risen 5.57% since its last report. The company recently reported that it has 1.46 million shares sold short, which is 6.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Kinsale Cap Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747141242_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kinsale Cap Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Kinsale Cap Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Kinsale Cap Gr's peer group average for short interest as a percentage of float is 2.25%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

KNSL

How Is The Market Feeling About Kinsale Cap Gr?

Tradeweb Markets's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TW#NYSE">TW</a>) short percent of float has risen 10.42% since its last report. The company recently reported that it has 1.85 million shares sold short, which is 1.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Tradeweb Markets Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747141236_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tradeweb Markets has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tradeweb Markets's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Tradeweb Markets's peer group average for short interest as a percentage of float is 4.21%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Tradeweb Markets's Recent Short Interest

Press Releases

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Comments

Rocket Pharmaceuticals

Rocket Pharmaceuticals (RCKT) Options

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL